Search clinical trials for: 14C-PF-06651600

Total 3962 results

Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Healthy Participants

China
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Pfizer

Completed

Bioavailability Study Of PF-06651600 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Not yet recruiting

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Healthy Volunteers
Pfizer

Completed

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Healthy Volunteers

Belgium
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Pfizer

Active, not recruiting

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Completed

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Healthy Volunteers | Pharmacokinetics | Adult

Belgium
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

PF-06651600 Taste Study.

Healthy Participants

Belgium
Pfizer

Completed

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

Healthy

United States
Pfizer

Completed

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Healthy

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Pfizer

Active, not recruiting

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (Allegro2a)

Alopecia Areata

United States, Australia, Canada, Poland
Pfizer

Completed

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Healthy Volunteers

United States
Pfizer

Completed

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Poland, Serbia, Slovakia, Czechia, Georgia, Germany, Bulgaria, Hungary
Pfizer

Completed

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

Healthy Volunteers

United States
Pfizer

Completed

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Active Non-segmental Vitiligo

Spain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
Pfizer

Completed

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects

Netherlands
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine
Pfizer

Completed

Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer

Neuroinflammation

United States
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Pfizer

Completed

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

HCV

United States
Pfizer

Withdrawn

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Healthy Participants
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
Bio-Thera Solutions

Recruiting

Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009

Locally Advanced/Metastatic Solid Tumours

China
Pfizer

Completed

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Healthy Volunteers

United States
Pfizer

Completed

A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Active, not recruiting

Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)

Alopecia Areata

United States, Spain, China, Korea, Republic of, Taiwan, Australia, Canada, Germany, Czechia, Poland, Japan, United Kingdom, Mexico, Argentina, Chile, Colombia, Russian Federation
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom

3

Subscribe